Story perspectives

Groundbreaking Cancer Research Unveiled at ESMO 2025 Congress

10/14/2025

Summary

Story summary

Foundation Medicine and Dana-Farber Cancer Institute will present at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Oct. 17–21.
Foundation Medicine will showcase 11 abstracts on FoundationOne Monitor and FoundationOne RNA tests with improved outcomes.
Dana-Farber will lead studies on breast, lung, and bladder cancers, focusing on quality of life and blood tests for guidance.
Natera will present 14 studies on molecular residual disease testing in cancer.

1 of 1

Story summary

Foundation Medicine and Dana-Farber Cancer Institute will present at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Oct. 17–21.
Foundation Medicine will showcase 11 abstracts on FoundationOne Monitor and FoundationOne RNA tests with improved outcomes.
Dana-Farber will lead studies on breast, lung, and bladder cancers, focusing on quality of life and blood tests for guidance.
Natera will present 14 studies on molecular residual disease testing in cancer.